Resultados de búsqueda - Zariana Nikolova

  • Mostrando 1 - 10 Resultados de 10
Limitar resultados
  1. 1
    A Novel Family of Serine/Threonine Kinases Participating in Spermiogenesis

    A Novel Family of Serine/Threonine Kinases Participating in Spermiogenesis por Peter Kueng, Zariana Nikolova, Valentin Djonov, Andrew Hemphill, Valeria Rohrbach, Dominik Boehlen, Gisela Zuercher, Anne‐Catherine Andres, Andrew Ziemiecki

    Publicado 1997
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors por George D. Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D. Blanke, Heikki Joensuu, Margaret von Mehren

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients

    Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients por Stefan Pursche, Eberhard Schleyer, Malte von Bonin, Gerhard Ehninger, Samir M. Said, Roland Prondzinsky, Thomas Illmer, Yanfeng Wang, Christian Hosius, Zariana Nikolova, Martin Bornhäuser, G. Dresemann

    Publicado 2008
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

    Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Ex... por Charles D. Blanke, George D. Demetri, Margaret von Mehren, Michael C. Heinrich, Burton Eisenberg, Jonathan A. Fletcher, Christopher L. Corless, Christopher D.�M. Fletcher, Peter Roberts‎, Daniela Heinz, Elisabeth Wehre, Zariana Nikolova, Heikki Joensuu

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

    Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma por Víctor Moreno, Juan Manuel Sepúlveda-Sánchez, María Vieito, Tatiana Hernández‐Guerrero, Bernard Doger, Omar Saavedra, Olga Ferrero, R. Sarmiento, M. Arias, Juan de Alvaro, Jorge Di Martino, Marlene Zuraek, Tania Sánchez‐Pérez, Ida Aronchik, Ellen Filvaroff, M. Lamba, Bishoy Hanna, Zariana Nikolova, Irene Braña

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

    Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma por David A. Reardon, G. Dresemann, Sophie Taillibert, Mario Campone, Martin J. van den Bent, Paul M. Clément, Erik Blomquist, Laurence Gordower, Henrik Schultz, Jeffrey Raizer, Peter Hau, Jacob C. Easaw, Miguel Gil‐Gil, J.-C. Tonn, Anja Gijtenbeek, Uwe Schlegel, Per Bergström, S. Green, Alexander Weir, Zariana Nikolova

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

    Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide por G. Dresemann, Michael Weller, Mark Rosenthal, Ulrich Wedding, W. Wagner, Erik Engel, Bernhard Heinrich, Regine Mayer‐Steinacker, Anders Karup-Hansen, Øystein Fluge, Anna K. Nowak, H. Maximilian Mehdorn, Eberhard Schleyer, Dietmar Krex, Ian Olver, Joachim P. Steinbach, C. Hosius, Christian Sieder, G. Brent Sorenson, Richard Parker, Zariana Nikolova

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

    Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta por Jane F. Apperley, Martine Gardembas, Junia V. Melo, R. Russell‐Jones, Barbara J. Bain, E. Joanna Baxter, Andrew Chase, Judith M. Chessells, Marie Colombat, Claire Dearden, Saša Dimitrijević, François-X. Mahon, David Marin, Zariana Nikolova, Eduardo Olavarría, Sandra Silberman, Beate Schultheis, Nicholas C.P. Cross, John M. Goldman

    Publicado 2002
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Clinical activity of <scp>CC‐90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies

    Clinical activity of <scp>CC‐90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies por Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, Patricia Niccoli, Jaume Capdevila, Giuseppe Curigliano, Víctor Moreno, Filippo de Braud, Sonia González de Villambrosía, Patricia Martín-Romano, Éric Baudin, Marina Arias, Juan de Alvaro, Josep Lluís Parra-Palau, Tania Sánchez‐Pérez, Ida Aronchik, Ellen Filvaroff, Manisha Lamba, Zariana Nikolova, Johann S. de Bono

    Publicado 2022
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders

    Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders por Marianna Dávid, Nicholas C.P. Cross, Sonja Burgstaller, Andrew Chase, Claire Curtis, Raymond Dang, Martine Gardembas, John M. Goldman, Francis Grand, George S. Hughes, Françoise Huguet, Louise Lavender, Grant A. McArthur, François Xavier Mahon, Giorgio Massimini, Junia V. Melo, Philippe Rousselot, R. Russell‐Jones, John F. Seymour, Graeme Smith, Alastair Stark, Katherine Waghorn, Zariana Nikolova, Jane F. Apperley

    Publicado 2006
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: